Crystal Engineering Approaches in Enhancing Solubility of BCS Class II Drugs: A Comprehensive Review on Pharmaceutical Co-crystals

Fig. 1: Solubility enhancement using pharmaceutical cocrystals

Fig. 2  The stages involved in cocrystal formation are shown via diagrams

Fig.3 Mechanisms of cocrystal formation

Fig.4 Advantages of cocrystals

The characterization of pharmaceutical co-crystals is a critical step to confirm their formation, structural integrity, and performance-related properties. A combination of analytical techniques is typically employed to obtain comprehensive information about the solid-state system. X-ray powder diffraction (XRPD) serves as a primary tool for confirming co-crystal formation by identifying unique diffraction patterns distinct from the parent components. Differential scanning calorimetry (DSC) provides insight into thermal behavior, including melting point shifts and phase transitions, which indicate the formation of a new crystalline phase.

 Fourier transform infrared spectroscopy (FTIR) is widely used to detect changes in functional group vibrations, thereby confirming intermolecular interactions such as hydrogen bonding between the API and co-former. Scanning electron microscopy (SEM) enables visualization of particle morphology and surface characteristics, which can influence dissolution behavior and processability. Additionally, thermogravimetric analysis (TGA) is essential for assessing thermal stability and detecting solvent or moisture content in the co-crystal system. Together, these techniques offer a robust framework for the qualitative and quantitative evaluation of co-crystals, ensuring their suitability for pharmaceutical development and regulatory compliance

REGULATORY ASPECTS OF CO-CRYSTALS:

Pharmaceutical co-crystals have gained significant regulatory recognition as distinct solid-state forms of active pharmaceutical ingredients (APIs), reflecting their growing importance in drug development. Unlike salts or polymorphs, co-crystals consist of an API and a neutral co-former in a definite stoichiometric ratio, held together by non-covalent interactions such as hydrogen bonding. Regulatory authorities have developed specific frameworks to address their classification, quality, and evaluation.According to the United States Food and Drug Administration (FDA), pharmaceutical co-crystals are generally classified as drug product intermediates rather than new molecular entities, provided that they dissociate into the API and co-former prior to reaching the site of pharmacological action. This classification has important implications for regulatory pathways, as it allows co-crystals to be developed without requiring full safety evaluation as new chemical entities, assuming the co-former is pharmaceutically acceptable. Similarly, the European Medicines Agency (EMA) recognizes co-crystals as a unique class of solid forms and requires comprehensive physicochemical characterization and justification of their performance advantages.Regulatory evaluation of co-crystals involves a thorough assessment of several critical parameters.  One of the key considerations is the dissociation behavior of the co-crystal in physiological media, ensuring that the API is released in its active form. Stability studies under varying environmental conditions, including temperature and humidity, are essential to evaluate the robustness of the co-crystal form during storage and handling. Additionally, polymorphic transformations must be carefully monitored, as different crystalline forms can significantly influence drug performance and reproducibility.Another important aspect is the impact of co-crystal formation on bioavailability and safety. Regulatory agencies require evidence that co-crystals provide consistent and predictable improvements in solubility and dissolution without introducing toxicity risks from the co-former. Therefore, the selection of co-formers is typically restricted to compounds with established safety profiles, such as those listed under Generally Recognized as Safe (GRAS) substances.Advanced analytical techniques, including powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and spectroscopic methods, are required to confirm co-crystal formation, purity, and stability. In addition, in vitro and in vivo studies may be necessary to demonstrate improved pharmacokinetic performance. Overall, regulatory guidelines ensure that pharmaceutical co-crystals meet stringent standards of quality, safety, and efficacy comparable to conventional drug formulations. As regulatory frameworks continue to evolve, they are expected to further streamline the development and approval of co-crystal-based drug products, thereby encouraging innovation while maintaining patient safety.

RECENT ADVANCES IN CO-CRYSTAL RESEARCH:

Recent advancements in pharmaceutical co-crystal research have significantly broadened their scope and applicability in modern drug development, particularly for poorly soluble BCS Class II drugs. One of the most notable developments is the increasing use of computational approaches, including molecular modeling, crystal structure prediction (CSP), and density functional theory (DFT). These tools facilitate the rational selection of suitable co-formers, prediction of intermolecular interactions, and evaluation of thermodynamic stability, thereby reducing the reliance on trial-and-error experimental methods. Green synthesis techniques have also gained considerable attention due to their environmental and economic advantages. Solvent-free methods such as mechanochemical grinding (neat grinding and liquid-assisted grinding) have emerged as efficient, scalable, and sustainable approaches for co-crystal production. These methods minimize solvent usage, reduce energy consumption, and offer improved control over crystal formation, aligning well with the principles of green chemistry.In addition, the development of nano co-crystals represents a promising strategy to further enhance dissolution rates and oral bioavailability. By reducing particle size to the nanometer scale, nano co-crystals provide a larger surface area and improved wettability, leading to faster drug release and enhanced absorption. This approach combines the benefits of nanotechnology with crystal engineering, offering a synergistic improvement in drug performance.The integration of artificial intelligence (AI) and machine learning (ML) into co-crystal research has further accelerated the discovery and optimization process. AI-driven models can analyze large datasets to predict co-crystal formation likelihood, screen potential co-formers, and optimize formulation parameters with high accuracy and efficiency. This data-driven approach is transforming traditional pharmaceutical development into a more predictive and streamlined process.Furthermore, advancements in characterization techniques—such as powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier-transform infrared spectroscopy (FTIR), and solid-state nuclear magnetic resonance (SSNMR)—have enabled detailed insights into co-crystal structures, stability, and phase transformations. These techniques ensure proper identification and quality control of co-crystal systems.Importantly, several co-crystal-based drug products have progressed to clinical and commercial stages, demonstrating their practical feasibility and regulatory acceptance. Regulatory agencies such as the US FDA and EMA have also established clear guidelines for the classification and evaluation of pharmaceutical co-crystals, further supporting their adoption in industry. Overall, these recent advances highlight the growing importance of co-crystals as a versatile and innovative platform for enhancing drug solubility, stability, and bioavailability. Continued progress in computational design, sustainable manufacturing, and advanced analytical techniques is expected to further expand their role in future pharmaceutical research and development.

FUTURE PERSPECTIVES

Pharmaceutical co-crystals have demonstrated significant potential in overcoming solubility and bioavailability challenges associated with poorly water-soluble drugs. With the continuous advancement of crystal engineering and supramolecular chemistry, the future of co-crystal technology appears highly promising in modern pharmaceutical development. The integration of computational modeling, artificial intelligence, and crystal structure prediction tools is expected to simplify the screening and selection of suitable co-formers, thereby reducing time and cost involved in formulation development. Emerging approaches such as nano co-crystals, green synthesis methods, and continuous manufacturing techniques are likely to further enhance the industrial applicability of pharmaceutical co-crystals. In addition, the growing focus on personalized medicine may create new opportunities for designing patient-specific co-crystal formulations with improved therapeutic performance. Advanced characterization techniques and process analytical tools are also expected to provide better understanding of co-crystal stability, polymorphism, and intermolecular interactions. Despite considerable progress, challenges related to large-scale manufacturing, long-term stability, regulatory harmonization, and commercial scalability still require further investigation. Future research should focus on developing environmentally sustainable preparation methods, improving predictive modeling approaches, and expanding the application of co-crystals for a wider range of therapeutic agents. Overall, pharmaceutical co-crystals are expected to play an increasingly important role in enhancing drug delivery and optimizing pharmaceutical formulation strategies in the coming years.

CONCLUSION

Pharmaceutical co-crystals have emerged as a robust, versatile, and scientifically advanced approach for addressing the persistent solubility and bioavailability challenges associated with BCS Class II drugs. By leveraging the principles of crystal engineering and supramolecular chemistry, co-crystals enable the rational design of solid forms that improve key physicochemical properties—such as solubility, dissolution rate, stability, and mechanical behavior—without altering the intrinsic molecular structure or pharmacological activity of the active pharmaceutical ingredient (API).The ability to fine-tune drug properties through the selection of suitable co-formers, guided by hydrogen bonding patterns, intermolecular interactions, and computational predictions, has significantly expanded the scope of formulation development.

 Moreover, advancements in characterization techniques, including PXRD, DSC, FTIR, and solid-state NMR, have enhanced the understanding of co-crystal formation mechanisms and structural attributes. The integration of computational tools and crystal structure prediction methods further supports the efficient screening and design of novel co-crystal systems.Importantly, the scalability of co-crystal production through techniques such as solvent evaporation, grinding, hot melt extrusion, and spray drying highlights their industrial feasibility. Several co-crystal-based formulations have already progressed to commercial and clinical stages, underscoring their practical relevance and regulatory acceptance. However, challenges such as polymorphism, stability under varying environmental conditions, and regulatory complexities still require careful consideration Despite these limitations, the future of pharmaceutical co-crystals remains highly promising. Continued research in green synthesis methods, advanced modeling techniques, and personalized medicine applications is expected to further enhance their utility. Overall, co-crystals represent a key enabling technology in modern drug development, offering a strategic pathway to overcome solubility limitations and improve therapeutic performance of poorly water-soluble drugs

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENT

The authors are thankful to Government College of Pharmacy, Karad for providing necessary support and facilities.

REFERENCES

1. Aakeröy CB, Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm. 2005;7:439–48.
2. Schultheiss N, Newman A. Pharmaceutical co-crystals and their physicochemical properties. Cryst Growth Des. 2009;9:2950–67.
3. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. Crystal engineering approach to forming co-crystals. J Am Chem Soc. 2004;126:13335–42
4. Almarsson Ö, Zaworotko MJ. Crystal engineering of pharmaceutical co-crystals. Chem Commun. 2004:1889–96.
5. Shan N, Zaworotko MJ. The role of co-crystals in pharmaceutical science. Drug Discov Today. 2008;13:440–6
6. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients. Adv Drug Deliv Rev. 2007;59:617–30
7. Brittain HG. Polymorphism in pharmaceutical solids. 2nd ed. CRC Press; 2009.
8. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical co-crystals: an overview. Int J Pharm. 2011;419:1–11
9. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical co-crystals and poorly soluble drugs. Int J Pharm. 2013;453:101–25
10. Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical co-crystals: regulatory and design aspects. Chem Commun. 2016;52:640–55.
11. Good DJ, Rodríguez-Hornedo N. Solubility advantage of pharmaceutical co-crystals. Cryst Growth Des. 2009;9:2252–64
12. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Co-crystals of pharmaceutical compounds. J Pharm Sci. 2011;100:2172–81.
13. Nangia A. Pharmaceutical co-crystals: a new paradigm. J Pharm Sci. 2017;106:2590–5.
14. Bag PP, Nangia A. Co-crystals of pharmaceuticals. Cryst Growth Des. 2012;12:5414–28
15. Grothe E, Meekes H, Vlieg E, ter Horst JH, de Gelder R. Solubility of pharmaceutical co-crystals. Cryst Growth Des. 2016;16:3237–43.
16. Yu ZQ, Chow PS, Tan RBH. Co-crystallization process development. J Pharm Sci. 2010;99:3995–4021
17. Rodríguez-Hornedo N, Nehm SJ, Jayasankar A. Cocrystals: design, properties and formation mechanisms. Encycl Pharm Technol. 2007
18. Zhang GGZ, Law D, Schmitt EA, Qiu Y. Phase transformation considerations. Adv Drug Deliv Rev. 2004;56:371–90.
19. Stahly GP. Diversity in single- and multiple-component crystals. Cryst Growth Des. 2007;7:1007–26.
20. Trask AV. An overview of pharmaceutical co-crystals. Mol Pharm. 2007;4:301–9
21. Karimi-Jafari M, Padrela L, Walker GM, Croker DM. Creating co-crystals: a review. Cryst Growth Des. 2018;18:6370–87
22. Karki S, Friš?i? T, Fábián L, Laity PR, Day GM, Jones W. Improving mechanical properties by co-crystal formation. Adv Mater. 2009;21:3905–9.
23. Friš?i? T, Jones W. Benefits of mechanochemistry. J Pharm Pharmacol. 2010;62:1547–59
24. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, et al. Use of co-crystals in drug development. Pharm Res. 2006;23:1888–97.
25. Etter MC. Hydrogen bonds in crystal engineering. Acc Chem Res. 1990;23:120–6.
26. Desiraju GR. Crystal engineering: a holistic view. Angew Chem Int Ed. 2007;46:8342–56.
27. Vishweshwar P, McMahon JA, Oliveira M, Peterson ML, Zaworotko MJ. The predictability of supramolecular synthons. J Am Chem Soc. 2005;127:16802–3
28. Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical co-crystals. Drug Discov Today. 2019;24:796–804.
29. Steed JW. The role of co-crystals in pharmaceutical design. Trends Pharmacol Sci. 2013;34:185–93.
30. Sun CC. Cocrystallization for pharmaceutical materials. Pharm Res. 2013;30:264–7.
31. FDA. Regulatory Classification of Pharmaceutical Co-crystals. Guidance for Industry. 2018
32. EMA. Reflection paper on pharmaceutical co-crystals. 2014.
33. Goud NR, Suresh K, Nangia A. Pharmaceutical co-crystals. Chem Commun. 2012;48:7352–65.
34. Suresh K, Goud NR, Nangia A. Crystal engineering. Cryst Growth Des. 2014;14:529–41.
35. Basavoju S, Boström D, Velaga SP. Pharmaceutical co-crystals. AAPS PharmSciTech. 2008;9:1086–93
36. Patel BP, Patel JK, Chakraborty S, Shukla D. Co-crystals: a novel approach. Int J Pharm Sci Rev Res. 2014;25:129–36.
37. Kale DP, Zode SS, Bansal AK. Challenges in co-crystal formation. Cryst Growth Des. 2017;17:3301–9.
38. Berry DJ, Steed JW. Pharmaceutical co-crystals. Adv Drug Deliv Rev. 2017;117:3–24.
39. He G, Jacob C, Guo L, Chow PS, Tan RBH. Screening of co-crystals. Cryst Growth Des. 2011;11:1398–405.
40. Sarma B, Nangia A. Co-crystals of APIs. CrystEngComm. 2009;11:1141–52.